Heterocyclic analogs of diphenylethylene compounds
申请人:Theracos, Inc.
公开号:US07407978B2
公开(公告)日:2008-08-05
Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.
NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE COMPOUNDS
申请人:Theracos, Inc.
公开号:EP1549625A1
公开(公告)日:2005-07-06
US7407978B2
申请人:——
公开号:US7407978B2
公开(公告)日:2008-08-05
US7718682B2
申请人:——
公开号:US7718682B2
公开(公告)日:2010-05-18
[EN] NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE COMPOUNDS<br/>[FR] NOUVEAUX ANALOGUES HETEROCYCLIQUES DE COMPOSES DE DIPHENYLETHYLENE
申请人:THERACOS INC
公开号:WO2004033438A1
公开(公告)日:2004-04-22
Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.